A Pilot Study of the Efficacy and Safety of Paroxetine Augmented With Risperidone, Valproate, Buspirone, Trazodone, or Thyroid Hormone in Adult Chinese Patients With Treatment-Resistant Major Depression
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
To compare the efficacy and safety of augmenting paroxetine with risperidone, buspirone, valproate, trazodone, or thyroid hormone in patients with treatment-resistant depression (TRD), 225 patients with retrospectively and/or prospectively identified stage II TRD were randomly assigned to receive an 8-week treatment of paroxetine 20 mg/d augmented with risperidone 2 mg/d (n = 45), sodium valproate 600 mg/d (n = 39), buspirone 30 mg/d (n = 46), trazodone 100 mg/d (n = 47), or thyroid hormone 80 mg/d (n = 48). The primary outcome was the remission rate defined as the 17-item Hamilton Rating Scale for Depression score of 7 or less at the end of study. Secondary outcomes included remission rate based on the Self-rating Depression Scale score of 50 or less at the end of study, response rate based on 17-item Hamilton Rating Scale for Depression total score of 50% improvement or greater from baseline, and the change in scores of Clinical Global Impression-Improvement scale, the Short Form 36 Health Survey, and the Life Satisfaction Rating Scale. The remission rates were 26.7% for risperidone, 48.7% for valproate, 32.6% for buspirone, 42.6% for trazodone, and 37.5% for thyroid hormone. There was no statistical significance among treatment arms in remission rates, secondary outcome measures, and adverse events. Risperidone, valproate, buspirone, trazodone, or thyroid hormone augmentation to paroxetine 20 mg/d was effective and well tolerated in Chinese patients with TRD. Large-sample studies are warranted to support or refute these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 1×
“In addition, residual symptoms are common even among so-called responders.(4) Patients who failed 2 or more antidepressants from different categories with adequate treatment durations and dosages are considered to have treatment-resistant depression (TRD).”
BackgroundRisperidone for Treatment-Refractory Major Depressive Disorder: A Randomized Trial
Mahmoud, R. A., Pandina, G. J., Turkoz, I., Kosik-Gonzalez, C., Canuso, C. M., Kujawa, M. J., & Gharabawi-Garibaldi, G. M. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-9-200711060-00003 · Cited by 140
Cited by
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis
Strawbridge, R., Carter, B., Marwood, L., Bandelow, B., Tsapekos, D., Nikolova, V. L., Taylor, R., Mantingh, T., de Angel, V., Patrick, F., et al. (2019) · British Journal of Psychiatry · doi:10.1192/bjp.2018.233 · Cited by 140
Henssler, J., Alexander, D., Schwarzer, G., Bschor, T., & Baethge, C. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.4313 · Cited by 111
Scott, F., Hampsey, E., Gnanapragasam, S., Carter, B., Marwood, L., Taylor, R. W., Emre, C., Korotkova, L., Martín-Dombrowski, J., Cleare, A. J., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221104058 · Cited by 87
Metadata
- Authors
- Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., Cui, X., Calabrese, J. R., & Gao, K.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2011-10
- Volume
- 31
- Issue
- 5
- Pages
- 638-642
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2014577629
- Cited by
- 59
- References
- 2
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Pilot Study of the Efficacy and Safety of Paroxetine Augmented With Risperidone, Valproate, Buspirone, Trazodone, or Thyroid Hormone in Adult Chinese Patients With Treatment-Resistant Major Depression. https://app.cochat.ai/papers/10.1097/jcp.0b013e31822bb1d9
- The paper
- Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., Cui, X., Calabrese, J. R., & Gao, K. (2011). A Pilot Study of the Efficacy and Safety of Paroxetine Augmented With Risperidone, Valproate, Buspirone, Trazodone, or Thyroid Hormone in Adult Chinese Patients With Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0b013e31822bb1d9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.